Study Investigates Asthma Drug’s Impact on Parkinson’s Disease

Overview of Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurological disorder marked by tremors, motor difficulties, and muscle discomfort. It arises from the degeneration and death of brain cells located in regions crucial for movement and muscle coordination. The accumulation of improperly shaped α-synuclein protein in these cells is believed to play a significant role in the disease’s progression. Consequently, drugs targeting α-synuclein, primarily aimed at inhibiting its aggregation, are being explored as potential treatments for PD. Recent research has shifted focus toward reducing the production of α-synuclein.

Research Findings on Salbutamol

A recent article in the journal Science details a study that explored the effects of various substances on α-synuclein production within brain cells. Researchers tested over 1,100 candidate drugs, vitamins, and supplements on brain cell cultures. Notably, salbutamol, a medication commonly prescribed for asthma, was found to decrease the activity of the α-synuclein gene (SNCA), thereby lowering α-synuclein protein levels.

The mechanism behind this effect involves the activation of the β2-adrenoreceptor (β2AR) by salbutamol, which not only aids in airway dilation but also reduces SNCA activity by enhancing histone acetylation. Histone proteins play a role in gene regulation by binding to DNA, where acetylation can alter their binding, making genes less accessible for transcription.

Impact of Salbutamol on Parkinson’s Disease Risk

To determine whether salbutamol use influences the risk of developing Parkinson’s disease, the researchers analyzed health records of over 4 million Norwegian patients over an 11-year span. Their findings revealed that individuals who had used salbutamol, even once, experienced a 34% reduction in the likelihood of developing PD. Furthermore, those who took higher doses of salbutamol from 2004 to 2007 were found to be 50% less likely to develop PD in the following years compared to those on lower doses. Conversely, the use of a compound that inhibits β2AR function was linked to an increased risk of PD. Despite these associations, the overall rate of PD in the population studied was low, with approximately 0.1% in non-salbutamol users and less than 0.04% in salbutamol users.

Additionally, β2AR activation has shown potential in reducing PD incidence in both mouse models and human brain cell cultures, indicating that salbutamol and similar drugs could be beneficial in the treatment and prevention of PD.

Future Directions for Research

These significant findings suggest that salbutamol may offer substantial benefits for treating Parkinson’s disease. More broadly, activating β2AR could represent an effective therapeutic approach for managing PD. Given that salbutamol does not easily penetrate the blood-brain barrier, further research into β2AR-activating compounds that can cross this barrier is warranted. Additionally, clinical studies involving more diverse populations with higher rates of Parkinson’s disease could enhance our understanding of the various factors influencing PD risk and the role of β2AR activation.

Clinical trials are currently underway to further explore these promising avenues.

Conclusion

The implications of this research could pave the way for new treatment strategies for Parkinson’s disease, potentially leveraging existing medications like salbutamol.

Author Information

Written by Raishard Haynes, MBS

References

http://www.sciencemag.org/news/2017/08/asthma-drug-may-thwart-parkinson-s-disease
http://science.sciencemag.org/content/357/6354/891